Canagliflozin (Invokana®)

Assessment Status NCPE Assessment Process complete
Drug Canagliflozin
Brand Invokana®
Indication Treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin
Assessment Process
Rapid review commissioned 25/11/2013
Rapid review completed 02/12/2013
Rapid review outcome Full HTA Recommended
Full submission received from Applicant 17/12/2014
NCPE assessment completed 29/08/2014
NCPE assessment outcome Reimbursement not recommended under the submitted pricing structure.

The HSE has approved reimbursement following confidential price negotiations; December 2014.

Technical Summary